Literature DB >> 28486460

Astex shapes CDK4/6 inhibitor for approval.

Mark Peplow.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28486460     DOI： 10.1038/nbt0517-395

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  Crystal structure of human CDK4 in complex with a D-type cyclin.

Authors:  Philip J Day; Anne Cleasby; Ian J Tickle; Marc O'Reilly; Joe E Coyle; Finn P Holding; Rachel L McMenamin; Jeff Yon; Rajiv Chopra; Christoph Lengauer; Harren Jhoti
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

2.  Pfizer's CDK4/6 inhibitor approved for advanced breast cancer.

Authors:  Chris Morrison
Journal:  Nat Biotechnol       Date:  2015-04       Impact factor: 54.908

3.  Fragment-based phenotypic screening is a hit.

Authors:  Monya Baker
Journal:  Nat Rev Drug Discov       Date:  2017-03-30       Impact factor: 84.694
  3 in total
  1 in total

1.  Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity.

Authors:  Marc Hafner; Caitlin E Mills; Kartik Subramanian; Chen Chen; Mirra Chung; Sarah A Boswell; Robert A Everley; Changchang Liu; Charlotte S Walmsley; Dejan Juric; Peter K Sorger
Journal:  Cell Chem Biol       Date:  2019-06-06       Impact factor: 8.116
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.